X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Axpaxli (axitinib) is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties. It is being developed for the treatment of diabetic retinopathy.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: Axpaxli
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Details:
Paxtrava (travoprost intracameral implant) is a prostaglandin analog. It is being evaluated for the treatment of patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: Paxtrava
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2024
Details:
The company intends to use the net proceeds from the private placement to accelerate the clinical development of Axpali (axitinib) for the treatment of wet age-related macular degeneration.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: Axpaxli
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Venrock Healthcare Capital Partners
Deal Size: $325.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 22, 2024
Details:
Axpaxli (axitinib) is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties. It is being developed for the treatment of wet age-related macular degeneration.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: Axpaxli
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
Axpaxli (axitinib) is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated in phase 3 trials for the treatment of wet AMD & other retinal diseases.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: Axpaxli
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
The company intends to use the proceeds to fund the Phase 3 clinical development of Axpaxli (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration, including its ongoing Phase 3 clinical trial and its planned second Phase 3 clinical trial.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: Axpaxli
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $115.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 18, 2023
Details:
The Company intends to use the proceeds to fund the Phase 3 clinical development of Axpaxli (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration, including its ongoing Phase 3 clinical trial and its planned second Phase 3 clinical trial.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: Axpaxli
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $100.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 13, 2023
Details:
Axpaxli (axitinib) is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet AMD & other retinal diseases.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: Axpaxli
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2023
Details:
OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet AMD and other retinal diseases.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: OTX-TKI
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
Dextenza (dexamethasone), a corticosteroid intracanalicular insert, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AffaMed Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
